Effect of Obesity on Prognosis After Early-Stage Breast Cancer

被引:430
作者
Ewertz, Marianne
Jensen, Maj-Britt
Gunnarsdottir, Katrin A.
Hojris, Inger
Jakobsen, Erik H.
Nielsen, Dorte
Stenbygaard, Lars E.
Tange, Ulla B.
Cold, Soren
机构
[1] Univ Southern Denmark, Odense Univ Hosp, Inst Clin Res, Odense, Denmark
[2] Aarhus Univ Hosp, Aarhus, Denmark
[3] Vejle Hosp, Vejle, Denmark
[4] Copenhagen Univ Hosp, Herlev Hosp, Copenhagen, Denmark
[5] Aarhus Univ Hosp, Aalborg Hosp, Aalborg, Denmark
关键词
BODY-MASS INDEX; EXPERIENCE;
D O I
10.1200/JCO.2010.29.7614
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose This study was performed to characterize the impact of obesity on the risk of breast cancer recurrence and death as a result of breast cancer or other causes in relation to adjuvant treatment. Patients and Methods Information on body mass index (BMI) at diagnosis was available for 18,967 (35%) of 53,816 women treated for early-stage breast cancer in Denmark between 1977 and 2006 with complete follow-up for first events (locoregional recurrences and distant metastases) up to 10 years and for death up to 30 years. Information was available on prognostic factors and adjuvant treatment for all patients. Univariate analyses were used to compare the associations of known prognostic factors and risks of recurrence or death according to BMI categories. Cox proportional hazards regression models were used to assess the influence of BMI after adjusting for other factors. Results Patients with a BMI of 30 kg/m(2) or more were older and had more advanced disease at diagnosis compared with patients with a BMI below 25 kg/m2 (P<.001). When data were adjusted for disease characteristics, the risk of developing distant metastases after 10 years was significantly increased by 46%, and the risk of dying as a result of breast cancer after 30 years was significantly increased by 38% for patients with a BMI of 30 kg/m(2) or more. BMI had no influence on the risk of locoregional recurrences. Both chemotherapy and endocrine therapy seemed to be less effective after 10 or more years for patients with BMIs greater than 30 kg/m(2). Conclusion Obesity is an independent prognostic factor for developing distant metastases and for death as a result of breast cancer; the effects of adjuvant therapy seem to be lost more rapidly in patients with breast cancer and obesity.
引用
收藏
页码:25 / 31
页数:7
相关论文
共 17 条
[1]   Body mass index as a prognostic feature in operable breast cancer:: the International Breast Cancer Study Group experience [J].
Berclaz, G ;
Li, S ;
Price, KN ;
Coates, AS ;
Castiglione-Gertsch, M ;
Rudenstam, CM ;
Holmberg, SB ;
Lindtner, J ;
Erzen, D ;
Collins, J ;
Snyder, R ;
Thürlimann, B ;
Fey, MF ;
Mendiola, C ;
Werner, ID ;
Simoncini, E ;
Crivellari, D ;
Gelber, RD ;
Goldhirsch, A ;
International Breast Cancer Study Grp .
ANNALS OF ONCOLOGY, 2004, 15 (06) :875-884
[2]   Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults [J].
Calle, EE ;
Rodriguez, C ;
Walker-Thurmond, K ;
Thun, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (17) :1625-1638
[3]   Obesity and weight change in relation to breast cancer survival [J].
Chen, Xiaoli ;
Lu, Wei ;
Zheng, Wei ;
Gu, Kai ;
Chen, Zhi ;
Zheng, Ying ;
Shu, Xiao Ou .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (03) :823-833
[4]   Weight loss in breast cancer patient management [J].
Chlebowski, RT ;
Aiello, E ;
McTiernan, A .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (04) :1128-1143
[5]   The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial [J].
de Azambuja, Evandro ;
McCaskill-Stevens, Worta ;
Francis, Prudence ;
Quinaux, Emmanuel ;
Crown, John P. A. ;
Vicente, Malou ;
Giuliani, Rosa ;
Nordenskjold, Bo ;
Gutierez, Jorge ;
Andersson, Michael ;
Vila, Mireia Margeli ;
Jakesz, Raimund ;
Demol, Jan ;
Dewar, Joanna ;
Santoro, Armando ;
Lluch, Ana ;
Olsen, Steven ;
Gelber, Richard D. ;
Di Leo, Angelo ;
Piccart-Gebhart, Martine .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) :145-153
[6]   Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer [J].
Dignam, JJ ;
Wieand, K ;
Johnson, KA ;
Fisher, B ;
Xu, L ;
Mamounas, EP .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (19) :1467-1476
[7]   Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer [J].
Ejlertsen, Bent ;
Mouridsen, Henning T. ;
Jensen, Maj-Britt ;
Andersen, Jorn ;
Cold, Soren ;
Edlund, Per ;
Ewertz, Marianne ;
Jensen, Brita B. ;
Kamby, Claus ;
Nordenskjold, Bo ;
Bergh, Jonas .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (05) :877-884
[8]   Population-Based Study of Peritumoral Lymphovascular Invasion and Outcome Among Patients With Operable Breast Cancer [J].
Ejlertsen, Bent ;
Jensen, Maj-Britt ;
Rank, Fritz ;
Rasmussen, Birgitte B. ;
Christiansen, Peer ;
Kroman, Niels ;
Kvistgaard, Marianne E. ;
Overgaard, Marie ;
Toftdahl, Dorte B. ;
Mouridsen, Henning T. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (10) :729-735
[9]  
Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.3.CO
[10]  
2-F